Month: June 2024

1931 posts
Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ — Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical…
The Strategic Advantage of Using Reqruit Asia for Recruitment

The Strategic Advantage of Using Reqruit Asia for Recruitment

As businesses continue to navigate the challenges of finding the right talent,…
Taipei Entrepreneurs Hub Presents: Invest and Start a Business in Taipei at InnoVEX 2024

Taipei Entrepreneurs Hub Presents: Invest and Start a Business in Taipei at InnoVEX 2024

TAIPEI, June 5, 2024 /PRNewswire/ — To attract international startups and foster…
State Grid Shandong Jining Sishui County Power Supply Company: "Busy Farming Season Ensures Power Reliability"

State Grid Shandong Jining Sishui County Power Supply Company: "Busy Farming Season Ensures Power Reliability"

JINING, China, June 5, 2024 /PRNewswire/ — "On June 4, with the…
Bybit's BTC Fund Pool Revolutionizes Wealth Management, Oversubscribed by VIPs in 7 Hours

Bybit's BTC Fund Pool Revolutionizes Wealth Management, Oversubscribed by VIPs in 7 Hours

DUBAI, UAE, June 5, 2024 /PRNewswire/ —  Bybit, one of the world’s…
Enjoy dinner anywhere on outdoor adventures with Stoke Voltaics' Nomad Cooking System

Enjoy dinner anywhere on outdoor adventures with Stoke Voltaics' Nomad Cooking System

Designed to electrify outdoor adventures over summer break, and make socializing fun…
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2…
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC

FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC

HEFEI, China, June 5, 2024 /PRNewswire/ — Kangpu Biopharmaceuticals today announced that…